Stem Cell Therapeutics Announces Issuance of Additional Patent
SCT is granted intellectual property protection in Japan
CALGARY, ALBERTA--(Marketwir
Therapeutics Corp. ("SCT")(TSX VENTURE:SSS) is pleased to announce
that the Company's strong intellectual property portfolio has been
enhanced by the addition of a patent granted in Japan.
This Japanese patent, numbered 3993560 and entitled "Combined
Regulation of Neural Cell Production" protects a pharmaceutical
composition for enhancing neuronal precursor cell formation in a
variety of central nervous system (CNS) disorders including brain
injury, stroke, Alzheimer's disease, Huntington's disease, and other
CNS diseases. The strategy of using a therapeutic regimen of drugs to
enhance neurogenesis, as taught in this patent, has the potential to
be a key treatment for many CNS diseases.
SCT is currently in a Phase IIa clinical trial with its lead
therapeutic regimen NTxTM-265, characterizing this approach as a
strategy to treat stroke patients. By exploiting the capacity of
endogenous adult neural stem cells to regenerate lost or
dysfunctional brain tissue as a means of recovering lost motor,
sensory or cognitive function, SCT is pursuing one of the most potent
therapeutic strategies currently in clinical development.
"We are very pleased with the issuance of this patent in Japan as it
not only extends our intellectual property coverage around the
concept of a drug-based approach to regenerate brain tissue but also
as its opens up additional clinical indications,
Moore, President and CEO of Stem Cell Therapeutics. "This patent
enhances our ability to pursue the use of Prolactin and
Erythropoietin (EPO) for the treatment of significant CNS diseases,
allowing us to widen our therapeutic scope initially focused on the
development of a treatment for stroke using Human Chorionic
Gonadotropin (hCG) and EPO. As such, we have already started to
assess the efficacy of a Prolactin-EPO regimen in a pre-clinical
model of Traumatic Brain Injury (TBI)."
About NTxTM-265: NTxTM-265 is an SCT developed therapeutic regimen of
two drugs. It targets the treatment of stroke by repurposing two
approved and clinically well-defined drugs. Human Chorionic
Gonadotropin (hCG) is the first drug administered in the regimen, and
aims to increase the number of neural stem cells (NSCs) located in
the brain of a patient suffering from a recent stroke. Erythropoietin
(EPO) is the second drug administered in the regimen, and aims to
promote the differentiation of these newly formed NSCs into new
neurons. New neurons thus formed are anticipated to provide benefit
to the patient through the replacement of the brain cells that were
lost or damaged by the stroke. Animal studies have shown a
significant recovery in motor function in animals that received the
NTxTM-265 regimen after a stroke. SCT is currently enrolling patients
in a phase IIa clinical trial in the United States and Canada in
order to investigate the safety and efficacy of NTxTM-265 in humans.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a
Canadian public biotechnology company (TSX VENTURE:SSS) focused on
the development and commercialization of drug-based therapies to
treat central nervous system diseases. SCT is a leader in the
development of therapies that utilize drugs to stimulate a patient's
own resident stem cells. The company's programs aim to repair
neurological function lost due to disease or injury. The company's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases.
These securities have not been registered under the United States
Securities Act of 1933, as amended, or the securities laws of any
state, and may not be offered or sold within the United States or to,
or for the account or benefit of U.S. persons unless an applicable
exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause but are not limited
to, changing market conditions, the successful and timely completion
of clinical studies, the establishment of corporate alliances, the
impact of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process and other
risks detailed from time to time in the Company's ongoing quarterly
and annual reporting.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
For more information, please contact
Stem Cell Therapeutics Corp.
Chloe Douglas-Crampton
Manager, Investor Relations
(403) 245-5495 ext. 221
Email: crampton@stemcellth
Website: www.stemcellthera.
or
MaisonBrison
Jean Walter
Vice-President
(514) 731-0000 ext. 223
Email: jean@maisonbrison.
http://www.marketwi
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
No comments:
Post a Comment